LifeVantage Corporation — Form 10-Q
Reporting period: Quarter and nine months ended March 31, 2012 (the third quarter of fiscal 2012, despite the request metadata referring to 2011 Q3). Unaudited consolidated results; comparisons are with the same periods ended March 31, 2011.
Business context and results
LifeVantage develops and sells dietary supplement Protandim and TrueScience skin care products, primarily through independent distributors in the Americas and Japan. Management attributes the sharp revenue increase to higher network-channel sales volume in both regions.
| Metric | Three months ended Mar. 31 | Nine months ended Mar. 31 |
|---|---|---|
| Net revenue, 2012 | $36.21 million | $81.58 million |
| Net revenue, 2011 | $9.98 million | $23.88 million |
| Gross profit margin, 2012 / 2011 | 86% / 84% | 86% / 84% |
| Operating income, 2012 / 2011 | $6.41 million / $0.79 million | $14.12 million / $1.75 million |
| Net income (loss), 2012 / 2011 | ($4.85 million) / ($9.77 million) | $7.64 million / ($3.60 million) |
| Operating cash flow, 2012 / 2011 | Not separately presented | $11.67 million / $2.45 million |
Financial position and liquidity
- At March 31, 2012, cash and cash equivalents were $16.90 million, versus $6.37 million at June 30, 2011. Working capital was $18.11 million, compared with a deficit of $3.11 million.
- Total assets were $33.38 million and total liabilities $10.85 million. Stockholders’ equity was $22.53 million, versus a $20.81 million deficit at June 30, 2011.
- The revolving credit line was paid off and closed in January 2012; no balance remained at quarter-end. Management said existing cash and anticipated operating cash flow should fund operations for at least 12 months, conditional on revenue and cash generation.
- Nine-month investing cash outflow was $1.44 million, mainly equipment purchases; financing cash inflow was $0.29 million, including option and warrant exercises, partly offset by stock repurchases and credit-line repayment.
Material changes and unusual items
- Revenue rose by $26.24 million for the quarter and $57.70 million for the nine-month period year over year. The filing attributes the increases to distributor-channel volume: Americas contributed $17.59 million and $38.58 million of the respective increases; Japan contributed $8.64 million and $19.14 million.
- Sales and marketing costs increased substantially with distributor commissions and growth-related hiring. Nine-month operating expenses rose to $55.84 million from $18.34 million. Management expects operating expenses to continue increasing as sales grow.
- Quarterly net loss reflected a $10.69 million charge from the change in fair value of derivative liabilities, despite $6.41 million of operating income. Nine-month results included a $6.74 million derivative fair-value charge. The filing reports no derivative liabilities at March 31 after warrant amendments and exercises.
- Nine-month tax benefit included a one-time $2.80 million release of the deferred-tax valuation allowance; realization of deferred tax assets depends on future earnings in relevant tax jurisdictions.
- The company recorded approximately $581,000 less in sales-return reserves in the quarter than under its prior estimate. The return reserve was $764,894 at March 31, versus $435,135 at June 30, 2011.
- Warrant and option exercises increased common shares outstanding; 109.22 million shares were outstanding at March 31 and 110.07 million at May 8, 2012. The company repurchased 678,926 shares for $0.98 million during the nine months.
Outlook, risks, and controls
- No specific revenue or earnings guidance was provided. Management expected gross margins to remain near the reported range and identified research and development spending of up to approximately 2% of net revenue for the remainder of the fiscal year, depending on projects and timing.
- Management identified reliance on a single principal product, distributor recruitment and retention, network-marketing and supplement regulation, product liability, third-party manufacturing, and international operations among business risks. A sales shortfall could require expense reductions; additional financing may be needed if cash generation falls short and could dilute shareholders.
- Disclosure controls and internal control over financial reporting were deemed ineffective at March 31 due to material weaknesses in accounting staffing and management oversight/documentation. Management said material audit adjustments had resulted from the weaknesses. It hired an Assistant Controller in April and planned further remediation and testing by June 30, 2012.
- Cash balances exceeded federally insured limits. The filing disclosed $11.25 million at one financial institution, approximately $0.90 million in foreign bank accounts, and $5.00 million in an investment management account.
- No material change in previously disclosed legal proceedings or risk factors was reported. No off-balance-sheet arrangements were reported.
Key facts for investors to verify
- Whether rapid sales growth and distributor productivity continue, particularly in Japan, and how concentrated revenue remains in Protandim.
- Whether the lower returns-reserve estimate is supported by subsequent return experience and whether reserve assumptions change.
- How much future reported earnings are affected by non-cash warrant or derivative accounting, and the extent of potential dilution from outstanding options and warrants.
- Whether deferred tax assets are ultimately realizable through future taxable income.
- Whether management remediates the disclosed material weaknesses on schedule and establishes effective financial-reporting controls.
- Whether operating cash flow remains sufficient to support growth, inventory needs, and planned research and development spending.